Skip to content

Embolization of Genicular Arteries for Treatment of Symptomatic Knee Osteoarthritis

Super Selective Angiographic Catheterization and Embolization of Genicular Arteries for Treatment of Symptomatic Knee Osteoarthritis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07736248
Enrollment
30
Registered
2026-07-30
Start date
2026-08-01
Completion date
2028-09-01
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angioembolization in Knee Osteoarthritis

Brief summary

To evaluate the efficacy and safety of genicular artery embolization in patients with symptomatic knee osteoarthritis refractory to conservative treatment.

Interventions

Super-selective embolization of abnormal genicular arteries supplying the painful synovium in patients with symptomatic knee osteoarthritis.

DEVICECalibrated microspheres (100-300 µm)

Embolic microspheres used for occlusion of the targeted genicular arteries during embolization.

A 2.0-2.4 Fr microcatheter used for super-selective catheterization of the genicular arteries.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of knee osteoarthritis according to the criteria of the American College of Rheumatology. Radiographic evidence of osteoarthritis corresponding to Kellgren-Lawrence grades I-III. Moderate to severe knee pain for at least 6 months. Visual Analog Scale (VAS) score ≥5. 2. Failure of conservative treatment for at least 3 months including analgesics, non-steroidal anti-inflammatory drugs, physiotherapy, lifestyle modification, or intra-articular injections.

Exclusion criteria

1. Kellgren-Lawrence grade IV osteoarthritis. 2. Previous knee arthroplasty. 3. Inflammatory arthropathies such as rheumatoid arthritis, psoriatic arthritis, or gout. 4. Active local or systemic infection. 5. Severe peripheral arterial disease. 6. Coagulation disorders. 7. Renal insufficiency (raised renal chemistry). 8. Pregnancy. 9. Known allergy to iodinated contrast media. 10. Refuse to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
change from baseline in visual analog scale (VAS) pain scoreBaseline and 6 months after the Procedurepain intensity measured using the 10-cm visual analog scale (VAS). scores range from 0 to 10, with higher scores indicating greater pain. The change from baseline to 6 months after genicular artery embolization will be assessed.

Secondary

MeasureTime frameDescription
Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total ScoreBaseline, 3 months, and 6 months after the procedureKnee pain, stiffness, and physical function will be assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The total WOMAC score ranges from 0 to 96, where 0 indicates no symptoms and 96 indicates the most severe symptoms. Higher scores indicate worse pain, stiffness, and functional limitation.
Change from Baseline in Health-Related Quality of Life Score (EQ-5D-5L)Baseline and 6 months after the procedureHealth-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The EQ-5D-5L descriptive system consists of five dimensions, each with five levels, and responses are converted into a utility index score ranging from values below 0 (health states worse than death) to 1.0 (full health), with higher scores indicating better health-related quality of life. Assessments will be performed at baseline, 3 months, and 6 months after the procedure.
Technical Success Rate of Genicular Artery EmbolizationDuring the procedureTechnical success is defined as successful selective catheterization and embolization of all target genicular arteries with completion of the planned procedure.

Contacts

CONTACTRehab Awad Mohamed
RehabAwad@aun.edu.eg2+01011511722
STUDY_DIRECTORMoustafa Hashim Mahmoud

Assiut University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026